



Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")

TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA

Cambridge, UK, 4 January 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetriss Pharma Ltd, has today launched Ogluo® (glucagon prefilled autoinjector pen) as a treatment for severe hypoglycaemia in children and adults living with diabetes in Austria, the second European launch in the Ogluo® European roll-out strategy.

See full Tetriss Pharma announcement below:

Tetriss Pharma European roll-out of Ogluo® continues with launch in Austria

A new treatment option for severe hypoglycaemia for children and adults living with diabetes

4 January 2023 - Tetriss Pharma Ltd ("Tetriss Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in Austria as a treatment for severe hypoglycaemia in adults, adolescent, and children aged two years and over living with diabetes mellitus.

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon to treat severe hypoglycaemia for people living with diabetes. There are an estimated 450,000 adults living with diabetes in Austria (IDF Atlas 10th Edition).

Ogluo® pricing has been published in Austria in the Warenverzeichnis (the reference for all Austrian pharmacies, insurers and wholesalers) managed by the Apotheker-Verlages®. Full prescribing information can be found [here](#). Today's launch in Austria builds on the roll-out of Ogluo® in Germany and Great Britain, as part of the pan-European commercialisation programme through which Tetriss Pharma intends to commercialise Ogluo® in core European markets. The Company is currently in discussions with various health authorities across Europe to ensure timely launches in additional major European countries.

"In Austria, people living with diabetes will now be able to receive Ogluo® to tackle severe hypoglycaemic events, enabling patients and those around to them to act quickly when such an event happens," **said Dr Shafiq Choudhary, Managing Director of Tetriss Pharma**, "With this launch in Austria, we look forward to expanding our reach within Europe over the coming months to bring this new treatment to people living with diabetes."

Enquiries:

Tetriss Pharma
Shafiq Choudhary +44 (0)1628 337579



Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo[®], a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance.

For further information, please visit tetrispharma.com

-ENDS-

For more information, please contact:

Areacor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com